Mayne Pharma has launched temozolomide capsules in the U.S. in 5mg, 20mg, 100mg, 140mg, 180mg and 250mg doses. The generic version of branded Temodar, temozolomide capsules are indicated for the treatment of adult patients with newly diagnosed cancerous brain tumors known as glioblastoma multiform concomitantly with radiotherapy and then as maintenance treatment. Temozolomide capsules had U.S. sales of approximately $150 million for the 12 months ending September 30, 2016, according to IMS He...